Viking Therapeutics (NASDAQ: VKTX) soared into the spotlight about a year ago when it delivered promising data on a drug ...

In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $28.87, denoting a +0.7% change from the preceding trading day.

We recently published a list of 10 Worst Performing Mid Cap Stocks to Buy According to Analysts. In this article, we are ...

Viking Therapeutics (NASDAQ: VKTX) and Novavax (NASDAQ: NVAX) were two of the big winners in the biotech industry last year.

We recently published a list of 10 Oversold Biotech Stocks to Buy Now. In this article, we are going to take a look at where ...

However, there are many contenders in the works. One of the most promising GLP-1 contenders is VK2735, a dual GLP-1/GIP ...

Viking advances VK2735 with a phase 2a study targeting results in H2'25. Phase 3 begins in Q2'25, fueling progress and ...

The Motley Fool has positions in and recommends Goldman Sachs Group and Pfizer. The Motley Fool recommends Novo Nordisk and Viking Therapeutics. The Motley Fool has a disclosure policy.

Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX – Get Free Report) have been assigned a consensus rating of “Buy” from the fifteen brokerages that are covering the firm, Ratings reports. One equities ...

Global Retirement Partners LLC trimmed its stake in Viking Therapeutics, Inc. (NASDAQ:VKTX – Free Report) by 19.8% during the ...

We came across a bullish thesis on Viking Therapeutics, Inc. (VKTX) on Substack by Kontra Investments. In this article, we ...

Few big pharma stocks have been bigger winners over the last three years than Eli Lilly and Novo Nordisk. Lilly now ranks as ...